The Breast Program - Translational Cancer Resource

Breast Cancer Clinical Trial

Official title:

The Breast Program - Translational Cancer Resource

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02798341
• Other study ID #: UPCC 08110
• Status: Active, not recruiting
• Start date: July 2012
• Est. completion date: July 2030

Study information

• Verified date: July 2023
• Source: Abramson Cancer Center at Penn Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

TRACR will provide a data/biospecimen repository for translational research to better diagnose, prognose, treat and cure breast cancer (and related diseases/treatment conditions). Patients at the Rowan Breast Center will be consented for donation of blood and if available tumor/healthy/archived tissue. Patients will be consented to give permission to use said specimens for future research and to be contacted in the future about other research participation and additional information.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 4000
• Est. completion date: July 2030
• Est. primary completion date: July 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• RBC patients with known invasive cancer pre-surgery (greater or equal to 1.5cm) are given priority in recruitment.

• RBC patients with known invasive cancer pre-surgery (less then 1.5cm). 3. RBC patients who are postsurgery for invasive breast cancer (performed at UPHS or non-UPHS entities).

• Patients that are of high risk for breast cancer (family history, known deleterious genetic mutation(s)) seeking a prophylactic mastectomy at the breast clinic.

• Only persons who can understand and give informed consent will be eligible to participate in this study. Furthermore, no persons belonging to vulnerable populations with as children (below 18 years of age), fetuses, neonates or prisoners will be recruited in this study. Pregnant women, who are pre-surgery and having surgery for clinical reasons, can still be recruited for tissue and blood collection.

Exclusion Criteria:

• Individual who cannot understand and give informed consent (cognitively impaired persons)

• Children (below 18 years of age), fetuses and neonates

• Prisoners

Related Conditions & MeSH terms

• Breast Cancer

Intervention

Other:
• Biospecimen Collection

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center at Penn Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of biospecimen collected		15 years